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Background: This research report evaluates clinical changes resulting
from local delivery of doxycycline hyclate (DH) or traditional scaling and
root planing (SRP) in a group of patients undergoing supportive periodontal
therapy (SPT).
Methods: In all, 141 patients received either DH (67) or SRP (74)
treatment in sites ≥5 mm on one-half of their dentition at baseline and
month 4.
Results: Clinical results were determined at month 9. Baseline mean
probing depth recordings were similar between the two groups (DH = 5.9
mm; SRP = 5.9 mm). Mean month 9 results showed similar clinical results
for attachment level gain (DH 0.7 mm; SRP 0.8 mm) and probing depth
reduction (DH 1.3 mm; SRP 1.1 mm). Percentage of sites showing ≥2 mm
attachment level gain at month 9 was 24.7% in the DH group and 21.2%
in the SRP group. Thirty-nine percent (39%) of DH sites and 38% of SRP
sites showed ≥2 mm probing depth reduction. When treated sides of the
dentition were compared to untreated sides, DH showed a difference in dis-
ease activity (≥2 mm attachment loss) from 19.3% (untreated) to 7.2%
(treated); and SRP from 14.3% (untreated) to 8.1% (treated).
Conclusions: Results show that both DH without concomitant mechan-
ical instrumentation and SRP were equally effective as SPT in this patient
group over the 9-month study period. J Periodontol 2000;71:22-30.
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T
he goal of supportive
periodontal therapy (SPT)
following active peri-
odontal treatment is to prevent
recurring disease episodes and
maintain the level of periodon-
tal health achieved during the
active treatment phase. Numer-
ous studies have demonstrated
and emphasized the impor-
tance of SPT in maintaining
susceptible patients’ periodon-
tal health (for a review, see ref-
erence 1).
Very little data are available
to determine the appropriate
SPT interval for an individual
periodontal patient. In the
absence of specific protocols
to individualize intervals, pa-
tients are usually seen every 3
to 6 months for repeat scaling
and root planing. Approxi-
mately 3 of 4 patients respond
well to this treatment.2-7 There-
fore, while routinely delivered
mechanical maintenance is
effective, approximately 20%
to 25% of patients have sig-
nificant additional periodontal
breakdown despite treatment.
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A second concern with SPT is patient compliance
with proposed SPT treatments. Research reports have
indicated that 34% to 42% of treated patients fail to
return for their first recall appointment following active
treatment.8,9 Compliance decreases over time follow-
ing treatment8-10 as well as with the complexity of
treatment.11 A number of factors have been suggested
that negatively affect compliance including skepticism,
unfavorable treatment benefit, treatment complexity,
time involved, economics, and stress.12 Unfortunately,
the most effective and conscientious periodontal ther-
apy is sometimes rendered ineffective because of
patients’ non-compliance with SPT.
The purpose of this study was to evaluate and com-
pare the clinical outcomes of two separate SPT treat-
ments in periodontal maintenance patients. The first of
these treatments was scaling and root planing; the sec-
ond was locally delivered controlled-release doxycy-
cline without concomitant mechanical instrumentation.
MATERIALS AND METHODS
This group of patients represents an SPT subgroup
from two previously reported randomized, blinded,
multicentered trials evaluating the safety and effec-
tiveness of locally delivered controlled-release doxy-
cycline. Clinical outcomes following doxycycline treat-
ment in these two parallel-design, 9-month studies
were compared to scaling and root planing (SRP), oral
hygiene (OH), and vehicle control (VC).13 In these
trials, clinical outcomes following doxycycline hyclate
(DH) and SRP treatments were superior to OH and
VC. Therefore, data from the OH and VC groups are
not included in this report.
This SPT subgroup of patients was identified by a
self-reported history of previous definitive periodontal
treatment defined as scaling and root planing by quad-
rant and/or periodontal surgery. In addition, patients
had to have undergone SPT for a minimum of 2 years
post-definitive treatment, with consistent recall inter-
vals ≤6 months over that period. Specifics of the
designs of the trials from which these patients were
selected have been previously published.13,14
Patients were included if they gave informed con-
sent, were 25 to 75 years of age, and had generalized
moderate to severe periodontitis. To qualify, patients
had at least 2 quadrants which each contained a min-
imum of 4 periodontal pockets ≥5 mm, that bled on
probing. Two of the qualifying sites were required to
have a probing depth ≥7 mm. Other details of the
exclusion/inclusion criteria have been published pre-
viously.14
DH and Treatment Procedures
The test formulation   containing doxycycline hyclate
was a solution containing 8.5% wt/wt doxycycline and
37% wt/wt poly(DL-lactide) (PLA) dissolved in a bio-
compatible carrier of 63% wt/wt N-methyl-2-pyrroli-
done (NMP). In the case of DH, the two components
of the formulation were provided in two separate
syringes that were coupled together just prior to use
and mixed for 100 cycles. Once mixed, the doxycy-
cline-containing test product was allowed to sit at room
temperature for 15 minutes and then mixed for another
10 cycles before use. A 23-gauge cannula was
attached to the delivery syringe, and the test product
was expressed into the periodontal pocket. Any over-
flow material was gently packed into the pocket with
a wetted curet. Quadrants treated with DH were cov-
ered with a periodontal dressing.¶¶¶ Patients treated
with DH returned at day 7 for removal of the dressing
and DH (subsequent studies have shown that removal
of DH is unnecessary; unpublished data). DH was
applied to each qualifying pocket on the treated side
of the mouth at the baseline and month 4 visits. Patients
in the DH treatment group were instructed not to per-
form oral hygiene on the treated side of the mouth dur-
ing each 7-day period following treatment. No con-
comitant mechanical instrumentation was provided. No
therapy other than OH was provided on the untreated
side of the mouth throughout the 9-month study period.
Patients randomized to the SRP group received a
single episode of SRP on the treated side of the mouth
at baseline and month 4. Therapists were instructed to
continue SRP until the treated root surfaces felt hard
and smooth to a dental explorer. Patients were given
local anesthesia on request. No time restraints were
placed on the SRP therapist; instead, treatment pro-
ceeded until the therapist was satisfied with the end-
point. SRP therapists were either periodontists or den-
tal hygienists chosen by the principal investigator. The
untreated side of the mouth did not receive any treat-
ment other than OH throughout the study. Patients
were instructed to begin oral hygiene on the treated
side of the mouth the day following SRP.
Patients in both the DH and SRP groups received
identical OH instructions. They were instructed in both
the Bass brushing technique and proper use of dental
floss to be performed 2 times a day. Compliance was
queried at each subsequent visit, and further instruc-
tion was provided as necessary.
Treatment Assignment and Blinding
All patients were randomized to treatment groups
according to a computer-generated random code. This
was a single-blind evaluation; the examiners at each
center were blinded to treatment. A double-blind design
was not possible because of the dissimilar treatments
between groups.
23
 Atridox, Block Drug Corporation, Inc., Jersey City, NJ.
¶¶¶ Coe-Pak periodontal dressing, GC America, Inc., Chicago, IL.
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Evaluations
A schedule of the evaluation timepoints and data col-
lection at each timepoint are outlined in Table 1. Mea-
surements of probing depth, bleeding on probing, clin-
ical attachment level, and plaque index15-17 were made
at these timepoints. Probing depth measurements were
made at 6 location points on all teeth in the dentition
(treated and untreated locations) using a periodontal
probe,### graduated in 1 mm increments with read-
ings made to the nearest millimeter. Four or five sites
in each of the 4 quadrants (treated and untreated) that
qualified for the study (≥5 mm with BOP) were selected
for attachment level measurements using the cemento-
enamel junction (CEJ) or other nearby landmark.
These attachment level sites on the treated one-half of
the dentition were a subset of the total sites evaluated
for probing depth, bleeding score, and plaque score
changes. There were continuous evaluations of both the
treated and untreated sides of the dentition through-
out the study, which allowed assessment of the bene-
fits of treatment on disease progression. Concomitant
medications and safety evaluations were recorded at
each visit. Any suspected adverse events or allergic
reactions were evaluated carefully by the investigator.
Further details concerning these evaluation appoint-
ments have been published previously.14
Statistical Methods
The patient groups from the two studies were combined
for this analysis after an ANOVA for study by treatment
interactions revealed no significant interactions when
the DH and SRP groups from the two studies were com-
bined. The efficacy endpoints were mean change in
attachment level and probing depth. Means were cal-
culated by using the sum of the treated and untreated
site measurements for a patient divided by the number
of treated and untreated sites. For all parameters, the
patient mean was the basis of the statistical analysis,
not the sites alone.18,19 Efficacy results for qualifying
treated and untreated sites for attachment level and
probing depth were analyzed statistically by analysis of
variance (ANOVA) on differences from baseline values
between groups. All statistical tests were conducted at
a significance level of P ≤0.05. All tests were two-tailed.
Exclusion of Tooth Sites
Sites on both the treated and untreated halves of the
dentition were excluded from the study at the discre-
24
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Table 1.
Schematic Outline of Study Procedures
Treatment Day
Screen Baseline Interim Day Month Month Interim Day 7 Months 
Visit 7 1, 2 4 Visit Post-Reapplication 5, 6, 8, 9
Informed consent X
Admission criteria X X
Pregnancy test X X X
Demographics X
Medical history X
Blood pressure and pulse rate X X X
Clinical photographs X X X X X X X X
Periodontal history X
Plaque index X X X X
Periodontal examination X X X X X
Administer treatments X X
Oral hygiene instruction X X ⋅ X X
Removal of periodontal dressing X ⋅ X X
Removal of test articles X X
Clinic visit X X X X X X X X X
J Periodontol • January 2000 Garrett, Adams, Bogle, et al.
tion of the principal investigator when they demon-
strated ≥2 mm attachment level loss from baseline at
two consecutive evaluations. Excluded sites were
treated with SRP and monitored at each subsequent
visit to be certain they were stable.
Procedures and criteria for study monitoring, pre-
study training, data management, and exclusion of
patients or investigators/centers have been described
previously14 and will not be reviewed in this report.
RESULTS
The efficacy parameters evaluated were mean change
in attachment level and mean change in probing depth.
ANOVA analyses are presented for data combined from
all centers in each study for each parameter and treat-
ment group. The number of patients per group avail-
able for analysis varied at each analysis timepoint
based on a blinded determination of whether they were
efficacy-evaluable at that particular study timepoint.
Patients were eliminated at various efficacy timepoints
when they presented outside the predetermined eval-
uation timepoints or had concomitant treatment, e.g.,
antibiotic therapy that may have altered the results.
Plaque score changes are presented as a measure-
ment of compliance. Bleeding on probing reductions
are also included. A total of 141 patients qualified for
the study – 67 DH-treated patients and 74 SRP-treated
patients. Sixty of the patients were female, and 81
were male. Median age was 50 years old.
Plaque Scores (PS) and Bleeding on Probing (BOP)
Baseline plaque scores were similar between treated
and untreated areas of the dentition and between DH
and SRP groups. Baseline PS ranged between 0.9 and
1.1. Reduction at month 9 ranged between 0.1 and
0.2. Reductions between treated and untreated areas
of the mouth and between treatments were not statis-
tically different (P >0.05). Baseline BOP ranged from
1.5 to 1.6 for both treated and untreated areas of the
dentition. Reductions at month 9 ranged from 0.4 to
0.6. Reductions between treated and untreated areas
were statistically significant in favor of the treated DH
and SRP groups.
Attachment Level Gain (ALG)
Table 2 shows ALG for all evaluated sites in the treated
and untreated halves of the dentition and for subgroups
of moderate (5 to 6 mm) and deep (≥7 mm) sites.
Results show no differences between SRP and DH
groups at either 4 or 9 months. Mean month 9 ALG
for all sites was 0.72 mm for DH and 0.75 mm for
SRP; for sites initially 5 to 6 mm, means were 0.65 mm
for DH and 0.58 mm for SRP; and for sites initially ≥7
mm, these means were 0.96 mm for DH and 1.02 mm
for SRP. Treated halves of the dentition show more
improvement than untreated areas. These differences
were usually significant (P ≤0.05), and mean improve-
ments were somewhat larger for untreated areas in DH
patients compared with untreated areas in SRP
patients.
Probing Depth (PD)
Table 3 shows PD reduction for all evaluated sites in
the treated and untreated halves of the dentition and
for subgroups of moderate (5 to 6 mm) and deep
(≥7 mm) sites. Results show no differences between
DH and SRP groups at 4 months. At month 9, DH
showed statistically better PD reduction in all sites and
sites 5 to 6 mm (P ≤0.05). Although statistically dif-
ferent, these differences were not clinically relevant.
Mean month 9 PD reduction for all sites was 1.28 mm
for DH and 1.13 mm for SRP. DH sites with baseline
PD 5 to 6 mm showed 1.11 mm reduction, and SRP
showed 0.92 mm reduction. Sites initially ≥7 mm
showed 1.76 mm reduction in the DH group and 1.67
mm in the SRP group. Again, treated areas of the den-
tition showed significantly greater improvement (P ≤
0.05) than untreated areas, and untreated areas in DH
patients showed somewhat more improvement than
untreated areas in SRP patients.
ALG and PD Reduction ≥2 mm
Tables 4 and 5 show the number of sites and per-
centage of sites that experienced significant clinical
change at month 9. Comparisons between DH and
SRP in both Table 4 (ALG) and Table 5 (PD reduc-
tion) show similar outcomes between the groups.
Approximately 30% of treated sites in both groups
showed ≥2 mm ALG. Approximately 40% in both
groups showed ≥2 mm PD reduction. These values are
generally double those of the untreated sides of the
dentition.
Sites Losing ≥2 mm Attachment Level
Table 6 compares the frequency and percentage of
sites with ≥2 mm attachment level loss in DH and SRP
treated groups. These values are compared to
untreated halves of the dentition in the same patient
groups. These data combine sites that were exited for
attachment level loss ≥2 mm during the study and
sites that showed this amount of loss at month 9. The
percentage of treated sites losing ≥2 mm of attach-
ment during the study was similar between DH and
SRP groups (7.2% and 8.1%, respectively). Treated
halves of the dentition showed a substantial reduction
in percentage of sites losing ≥2 mm attachment com-
pared to untreated sides. In this intra-treatment group
comparison, SRP showed a 43% reduction, and DH
showed a 63% reduction.
DISCUSSION
Results of this retrospective analysis of patients under-
going supportive periodontal treatment (SPT) are con-
sistent with the overall response seen in the large mul-
25
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Table 2.
Evaluation of Maintenance Patients—Attachment Level Gain (mean and SE)
All Sites Baseline Change at Month 4 Change at Month 9
DH
Treated sites 6.04 (0.30) 0.59 (0.12) 0.72 (0.13)
n = 67 n = 59 n = 59
Untreated sites 5.16 (0.23) 0.33 (0.07) 0.46 (0.09)
n = 67 n = 59 n = 59
SRP
Treated sites 5.51 (0.20) 0.60 (0.08) 0.75 (0.09)
n = 74 n = 67 n = 70
Untreated sites 5.34 (0.24) 0.30 (0.08) 0.34 (0.08)
n = 74 n = 67 n = 70
DH vs. SRP 0.7995 0.4891
DH vs. untreated 0.0317 0.0354
SRP vs. untreated 0.0072 0.0002
5 to 6 mm Baseline Probing Depth
DH*
Treated sites 5.23 (0.27) 0.54 (0.10) 0.65 (0.11)
n = 65 n = 57 n = 56
Untreated sites 4.88 (0.25) 0.23 (0.07) 0.44 (0.09)
n = 65 n = 57 n = 56
SRP
Treated sites 4.87 (0.20) 0.44 (0.08) 0.58 (0.09)
n = 74 n = 67 n = 70
Untreated sites 5.07 (0.23) 0.29 (0.08) 0.34 (0.09)
n = 74 n = 67 n = 70
DH vs. SRP 0.7230 0.2830
DH vs. untreated 0.0085 0.1018
SRP vs. untreated 0.1587 0.0228
≥7 mm Baseline Probing Depth
DH**
Treated sites 7.32 (0.35) 0.65 (0.16) 0.96 (0.17)
n = 64 n = 55 n = 55
Untreated sites 6.47 (0.28) 0.61 (0.18) 0.57 (0.18)
n = 47 n = 41 n = 42
SRP
Treated sites 6.94 (0.29) 0.82 (0.13) 1.02 (0.14)
n = 71 n = 66 n = 66
Untreated sites 6.83 (0.39) 0.34 (0.16) 0.54 (0.16)
n = 45 n = 42 n = 42
DH vs. SRP 0.2160 0.6022
DH vs. untreated 0.7718 0.1406
SRP vs. untreated 0.0013 0.0205
*   Two patients in the DH group did not have AL sites with pockets measuring 5 to 6 mm at baseline.
** Three patients in the DH group did not have AL sites with pockets measuring ≥ 7 mm at baseline.
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Table 3.
Evaluation of Maintenance Patients—Probing Depth Reduction (mean and SE)
All Sites Baseline Change at Month 4 Change at Month 9
DH
Treated sites 5.93 (0.05) −0.98 (0.09) −1.28 (0.09)
n = 67 n = 59 n = 59
Untreated sites 5.68 (0.07) −0.46 (0.07) −0.66 (0.09)
n = 64 n = 59 n = 59
SRP
Treated sites 5.86 (0.05) −1.00 (0.09) −1.13 (0.09)
n = 74 n = 67 n = 70
Untreated sites 5.58 (0.05) −0.55 (0.06) −0.55 (0.07)
n = 74 n = 67 n = 70
DH vs. SRP 0.6306 0.0294
DH vs. untreated 0.0001 0.0001
SRP vs. untreated 0.0001 0.0001
5 to 6 mm Baseline Probing Depth
DH
Treated sites 5.36 (0.02) −0.86 (0.08) −1.11 (0.08)
n = 67 n = 59 n = 59
Untreated sites 5.28 (0.03) −0.37 (0.07) −0.57 (0.09)
n = 67 n = 59 n = 59
SRP
Treated sites 5.33 (0.02) −0.83 (0.07) −0.92 (0.08)
n = 74 n = 67 n = 70
Untreated sites 5.26 (0.02) −0.53 (0.07) −0.52 (0.07)
n = 74 n = 67 n = 70
DH vs. SRP 0.4268 0.0302
DH vs. untreated 0.0001 0.0001
SRP vs. untreated 0.0018 0.0001
≥7 mm Baseline Probing Depth
DH
Treated sites 7.54 (0.07) −1.22 (0.14) −1.76 (0.14)
n = 67 n = 58 n = 58
Untreated sites 7.44 (0.09) −0.78 (0.14) −1.02 (0.17)
n = 50 n = 44 n = 44
SRP
Treated sites 7.56 (0.09) −1.51 (0.15) −1.67 (0.15)
n = 74 n = 66 n = 68
Untreated sites 7.44 (0.08) −0.77 (0.10) −0.90 (0.13)
n = 48 n = 45 n = 45
DH vs. SRP 0.7429 0.1574
DH vs. untreated 0.0266 0.0008
SRP vs. untreated 0.0001 0.0001
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ticenter trials from which this patient subset was
derived. In these two multicenter trials, outcomes
between DH and SRP groups were clinically equiva-
lent13 as they were in this analysis. There were no clin-
ical and only minor statistical differences in ALG, PD
reduction, and BOP reduction when SPT was accom-
plished by DH treatment without concomitant instru-
mentation or by traditional SRP.
Of particular importance was the impact of each of
these therapies on the rate of disease progression in
the patient’s dentition. The study design allowed intra-
patient comparisons of disease activity in monitored
sites on treated and untreated halves of the dentition
over the 9-month study period. Disease progression
was defined as sites that showed a loss of attachment
level ≥2 mm over the 9-month study period. There
was an approximate 63% difference in activity com-
paring treated and untreated areas of the dentition fol-
lowing DH, and a 43% difference following SRP treat-
ment. In this patient population, overall disease activity
was higher than expected.20-22 This may relate to the
population being evaluated. These were patients who
had received definitive periodontal care and had been
compliant with SPT visits (≤6-month intervals) for at
least 2 years. Despite this, they qualified to enter the
study by having at least 2 quadrants that each had 4
or more sites ≥5 mm that bled on probing. Two of
these sites had to be ≥7 mm. This likely represents an
increased disease activity compared to a general SPT
population.20-22 Additionally, the rate of disease activ-
ity in both the treated and untreated halves of the den-
tition may have been influenced by not treating the
entire dentition. Several recent research reports indi-
cate that full-mouth treatment, rather than a quadrant
or split-mouth approach, results in a more positive
clinical response overall which may be due to the
decreased overall bacterial load.23,24 These data are
strong evidence of the benefit of frequent SPT in sim-
ilar patient populations.
Research indicates that tetracyclines may be used
in conjunction with SRP in SPT patients25,26 or as a
monotherapy in refractory SPT patients27 with con-
siderable success. These data indicate that DH may
have potential use as an alternate treatment to SRP at
SPT visits where root planing is not required. These DH
treatments, used periodically when clinical conditions
indicate, may improve the generally poor visit com-
pliance seen in SPT patients.8-11 Lack of visit compli-
ance negatively affects outcomes following definitive
periodontal treatment.22,28,29 It is unknown whether
28
Table 6.
Sites Losing ≥2 mm Attachment Level
Total Sites Losing Sites* %
DH
Treated 512 37 7.2
Untreated 502 97 19.3
SRP
Treated 627 51 8.1
Untreated 558 80 14.3
* Combined sites with ≥2 mm attachment loss at month 9 and sites exited
from study because of ≥2 mm attachment loss.
Table 4.
Evaluation of Maintenance Patients—
Attachment Level Change ≥2 mm
Treated Sites Untreated Sites
N % N %
≥2 mm improvement
DH 157 31.2 107 24.7
SRP 177 29.4 110 21.2
≥2 mm loss
DH 29 5.8 29 6.7





Evaluation of Maintenance Patients—
Probing Depth Change ≥2 mm
Treated Sites Untreated Sites
N % N %
Reduction 2 mm
DH 405 39.2 150 19.6
SRP 460 37.5 177 19.9
Gain 2 mm
DH 7 0.7 16 2.1
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use of treatment alternatives to routine root planing
will improve visit compliance in SPT patients. Addi-
tional studies are necessary to demonstrate any
improvements in compliance.
Treatment with DH seemed to result in a modest
crossover effect to untreated halves of the dentition,
despite the somewhat higher incidence of sites losing
≥2 mm of attachment level in the DH group. Gener-
ally, mean improvement in ALG and PD reduction was
slightly greater in untreated areas of DH patients com-
pared with SRP patients. This may be a result of cross-
over of DH from treated to untreated areas of the den-
tition. A recent pharmacokinetic study has shown
modest levels of doxycycline in the saliva following
DH treatment of half the dentition.30 This reinforces
the importance of a parallel rather than split-mouth
design when evaluating similar products.
One drawback of the study is its 9-month design with
repeat treatment at month 4. This provides no infor-
mation regarding whether DH treatment may prolong the
SPT interval as has been suggested following use of
tetracycline-impregnated fibers.26 In addition, 9-month
data with only two treatments provide little information
regarding long-term effects of DH treatment. One recent
report has shown little long-term benefit following use
of tetracycline fibers.31 However, this report contained
relatively few patients and, as the authors suggested, the
data may have been skewed by patients in the fiber
group that showed unusually high rates of disease activ-
ity. This illustrates the necessity of properly powered
evaluations to assess outcomes. Other reports have
demonstrated long-term stability following tetracycline
fiber application.32 Finally, stability of outcomes fol-
lowing any type of periodontal therapy is SPT depen-
dent.1,7 It is assumed that DH-treated patients in rou-
tine clinical practice will eventually require root planing
as a part of ongoing SPT. Therefore, significantly longer-
term results that do not include root planing as part of
SPT may not be available.
In conclusion, this study demonstrates that SPT using
DH (without concomitant mechanical treatment) is as
effective as SRP in reducing the clinical signs of peri-
odontitis over 9 months. This suggests that DH treatment
may be an effective SPT treatment in patients who do
not require root planing at their SPT visit. Additional
studies are necessary to demonstrate the feasibility of
this treatment routine and whether it will improve SPT
compliance. Both DH and SRP demonstrated positive
effects on the rate of disease progression compared with
untreated areas in patients’ dentition. This emphasizes
the importance of frequent SPT visits and compliance
with these visits in maintaining periodontal health.
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